Candesartan targeting of angiotensin II type 1 receptor demonstrates benefits for hypertension in pregnancy via the NF-κB signaling pathway

XUDONG ZHAO¹,² and XIETONG WANG¹,²

¹Department of Gynecology and Obstetrics, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021; ²Department of Gynecology and Obstetrics, The Central Hospital of Taian City, Taian, Shandong 271000, P.R. China

Received September 12, 2016; Accepted December 13, 2017

DOI: 10.3892/mmr.2018.9070

Abstract. Hypertensive disorders may be a complication of pregnancy and are characterized by the high blood pressure. Evidence suggests that alterations in the renin-angiotensin-aldosterone system and the sympathetic nervous system are associated with gestational hypertension. Angiotensin II type 1 receptor (Ang-IITR) is a potential target in the progression of gestational hypertension. Candesartan is selective Ang-IITR antagonist that may act against vasoconstriction and reduces peripheral vascular resistance. The aim of the present study was to evaluate the efficacy of Candesartan and the underlying molecular mechanism of the nuclear factor-κB (NF-κB) signaling pathway in the progression of gestational hypertension in a mouse model. Expression and activity of Ang-IITR was evaluated in a mouse model of gestational hypertension prior to and post-treatment of Candesartan both in vitro and in vivo. It was determined whether Candesartan treatment reduces higher blood pressure and activated the renal renin-angiotensin system and a prognostic marker, soluble endoglin, and its associated gene in mice with gestational hypertension. Angiotensin-converting enzyme plasma levels and activity were also evaluated in the present study. Cytoplasmic and nuclear immunostaining of NF-κB (NF-κB) and associated proteins transforming growth factor β (TGF-β) and endoglin was enhanced in vascular endothelial cells and mice with gestational hypertension. Soluble fms-like tyrosine kinase 1 (sFlt-1), insulin resistance homeostasis and associated cardiovascular risk factors also were measured. Results demonstrated that angiotensin and Ang-IITR expression levels were upregulated in mice with gestational hypertension and were downregulated by Candesartan treatment. Renal renin-angiotensin and soluble endoglin were also improved in mice in the Candesartan-treated group. In addition, Candesartan treatment enhanced NF-κB activity, as well as TGF-β and vascular endothelial growth factor expression which led to improved levels of sFlt-1, insulin resistance homeostasis and associated cardiovascular risk factors. Gestational hypertension was markedly improved by treatment of Candesartan compared with the control. In conclusion, the findings of the present study suggested that the NF-κB signaling pathway may be involved with Candesartan-mediated Ang-IITR for the treatment of gestational hypertension.

Introduction

Gestational hypertension is a complication that specifically occurs in late pregnancy, and includes gestational hypertension, preeclampsia, eclampsia and chronic hypertension (1,2). A clinical investigation suggested that hypertensive disorder is a complication during pregnancy, is a common pregnancy-associated disease and is becoming increasingly present worldwide (3). However, the etiology of gestational hypertension is yet to be clearly investigated. Currently, insulin resistance, renin-angiotensin-aldosterone system (RAS) dysfunction, inflammation, obesity-induced interaction of neurohumoral and renal mechanisms are considered to be contributing factors of gestational hypertension (4,5). In addition, genetic factors that contribute to gestational hypertension have been well documented in a previous study (6). Furthermore, gestational hypertension seriously affects the life expectancy of the mother and fetus in the clinical setting (7,8). Gestational hypertension is one of the leading causes of maternal, fetal and neonatal morbidity and mortality (4,9). Reports have suggested that the incidence rate of gestational hypertension is approximately 7-12% in China, presenting a higher than the average incidence throughout the world (10).

Evidence has revealed that clinical assisted reproductive technology treatment, including artificial insemination and ovulation induction, may increase the incidence of gestational
hypertension and preeclampsia (11). In addition, there are a large number of factors that may induce gestational hypertension, and have been found to serve a role in the etiology of these hypertensive disorders, including work stress, depression and anxiety (12,13). Reports also have indicated that angiotensin II type 1 receptor (Ang-II), vasodilating converting enzyme (VCE) and α-1A adrenergic receptor (α-ADR) serve crucial roles in the process of gestational hypertension and may be potential targets for the treatment of patients with gestational hypertension in clinical (3,12,13). Therefore, a large number of drugs targeting Ang-II were introduced and their therapeutic effects for the treatment of gestational hypertension were evaluated.

Ang-II has been demonstrated to be a potential target in the progression of gestational hypertension and higher expression levels of this receptor exist in vascular endothelial cells in patients with gestational hypertension, compared with healthy pregnant women (14,15). Antihypertensive agents targeting Ang-II are the most common used drugs for remission patients with gestational hypertension (16,17). Candesartan (C20H20N4O2), is an antihypertensive drug, and is a selective Ang-II antagonist that acts by reducing peripheral vascular resistance and vasoconstriction (18,19). Candesartan is used to treat hypertension and prevents the constriction (narrowing) of blood vessels, including veins and arteries. In addition, fibrinolysis and insulin sensitivity was improved by treatment with Imidapril and Candesartan in patients with hypertension (20). The effect of Candesartan treatment on lipid metabolism in patients with hypertension has also been investigated in a retrospective longitudinal survey (21). However, the efficacy of Candesartan for gestational hypertension has not been previously studied.

In the present study, the therapeutic effects of Candesartan on gestational hypertension in a mouse model was investigated, in addition to the underlying molecular mechanisms by which it contributes to attenuating gestational hypertension induced by homocysteine. The aim of the present study was to characterize alterations in Ang-II, soluble fms-like tyrosine kinase 1 (sFlt-1), insulin resistance homeostasis model assessment score and associated cardiovascular risk factors in mice with gestational hypertension after treatment with Candesartan. NF-κB activation and nuclear factor NF-κB p65 subunit (p65), inhibitor of NF-κB kinase subunit β (IKK-β) and NF-κB inhibitor α (IκBα) expression levels were also investigated in vascular endothelial cells in mice treated by Candesartan.

**Materials and methods**

**Ethics statement.** The present study was carried out in strict accordance with the recommendations in the Guide for Shandong Provincial Hospital affiliated to Shandong University. All surgery and euthanasia were performed to minimize suffering. This study was approved by the ethics committee of Shandong University and Taian City Central Hospital (Jinan, China).

**Cell culture and reagents.** Vascular endothelial cells were isolated from experimental mice and cultured in Minimum Essential media (Merck KGaA, Darmstadt, Germany) supplemented with 10% fetal bovine serum (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA). Vascular endothelial cells were cultured at 37°C in a humidified atmosphere of 5% CO2. Cells were treated with Candesartan and/or NF-κB activity inhibitor JSH23 (Sigma-Aldrich; Merck KGaA) for 12 h at 37°C.

**Reverse transcription-quantitative polymerase chain reaction (RT-qPCR).** Total RNA was extracted from vascular endothelial cells by using an RNAeasy Mini kit (Qiagen GmbH, Hilden, Germany). RNA was reversed to cDNA using a one-step reverse transcription kit (Thermo Fisher Scientific, Inc.). Vascular endothelial growth factor (VEGF), transforming growth factor β (TGF-β), angiopoietin-1 (Ang-1), placental growth factor (PLGF), angiotensin, Ang-II, cytokine-induced neutrophil chemoattractant 1 (CINC-1), lipopolysaccharide induced CXC chemokine (LIX), monokine, α-ADR expression levels in vascular endothelial cells were determined by RT-qPCR with β-actin as an endogenous

**Western blot analysis.** Vascular endothelial cells were homogenized in radioimmunoprecipitation assay lysis buffer (Sigma-Aldrich; Merck KGaA) containing protease-inhibitor and centrifuged at 6,000 x g at 4°C for 10 min. The resulting supernatant was used for analysis of proteins. Protein concentration was determined with a bicinchoninic acid protein assay kit. Protein (10 μg/lane) was separated by 12.5% SDS-PAGE and subsequently transferred onto polyvinylidene fluoride membranes as previously described (22). For western blotting, membranes were incubated with the following primary antibodies for 12 h at 4°C: Superoxide dismutase (SOD; 1:1,000; cat. no. A91960Hu01; Shanghai Wuqi Biotechnology Co., Ltd., Shanghai, China) sFlt-1 (1:1,000; cat. no. ab230516), tumor necrosis factor α (TNF-α; 1:1,000; cat. no. ab6671), interleukin-2 (1:1,000; cat. no. ab80780), reactive oxygen species (ROS; 1:1,000; cat. no. ab191522), transcription factor p65 (1:1,000; cat. no. ab16502), inhibitor of nuclear factor κ B kinase subunit β (Iκκ-β; 1:1,000; cat. no. ab17870), NF-κB inhibitor α (IκBα; 1:1,000; cat. no. ab16502) and β-actin (1:1,000; cat. no. ab8227; all Abcam, Cambridge, MA, USA) were added following blocking in 5% skimmed milk for 60 min at 37°C. After washing with PBS three times, horseradish peroxidase-conjugated goat anti-rabbit IgG monoclonal secondary antibodies (1:2,000; cat. no. PV-6001; OriGene Technologies, Inc., Beijing, China) were added for 2 h at 37°C. The results were visualized with chemiluminescence substrate (Roche Diagnostics, Basel, Switzerland). Band density was analyzed by Quantity One software (version 4.62; Bio-Rad Laboratories, Inc., Hercules, CA, USA).

**Animal study.** Female C57BL/6 mice (aged 8 weeks; 25-30 g) were purchased from Jackson Laboratory (Ben Harbor, ME, USA) and housed in a 12 h light-dark cycle at 23±1°C with a relative humidity of 50±5%. All mice had free to access food and water. The mouse model of gestational hypertension was established according to previous studies (23,24). Mice with gestational hypertension were divided into two groups and received treatment with Candesartan (0.2 mg/kg) or with PBS as a control once daily for a total of 7 days.
control (25) (Invitrogen; Thermo Fisher Scientific, Inc.). All forward and reverse primers were synthesized by Invitrogen; Thermo Fisher Scientific, Inc. (Table I). The thermocycling conditions were as follows: Initial denaturation at 94°C for 2 min, followed by 35 cycles of 95°C for 30 sec, 54°C for 30 sec and 72°C for 10 min. The reaction volume (50 µl) contained 50 ng genomic cDNA, 200 µM dNTPs, 200 µM primers, and 72°C for 10 min. The reaction volume (50 µl) contained 2.5 U Taq DNA polymerase (Thermo Fisher Scientific, Inc.) (Table I). The thermocycling conditions were as follows: Initial denaturation at 94°C for 2 min, followed by 35 cycles of 95°C for 30 sec, 54°C for 30 sec and 72°C for 10 min. The reaction volume (50 µl) contained 50 ng genomic cDNA, 200 µM dNTPs, 200 µM primers, 2.5 U Taq DNA polymerase (Thermo Fisher Scientific, Inc.) and 2.5 U SYBR-Green (Thermo Fisher Scientific, Inc.). Relative mRNA expression levels were calculated by the 2-△△Cq method (26). The results are expressed as the n-fold way compared to control.

**Table I. Primer sequences used for reverse transcription-quantitative polymerase chain reaction.**

| Gene name | Reverse primer | Forward primer |
|-----------|----------------|----------------|
| Angiotensin | 5'-GCAAGGCGAAGACACTAAC-3' | 5'-GGGTCGTTAATCCCATGATG-3' |
| Ang-ITR | 5'-AAGGAGCTTCCGTAAAGCGG-3' | 5'-GGTATCTCTTACGTTACC-3' |
| VEGF | 5'-TTGCTGCTCTACCTCCAC-3' | 5'-GGGCAGTGATATCCGCAGCA-3' |
| TGF-β | 5'-CCCTGGAGGGCTCAACAC-3' | 5'-AAAAGTATGACAGGACGATG-3' |
| Ang-1 | 5'-GAAGGAAGCCAGGCCCTATTAC-3' | 5'-GGCAAGGCGAAGACACTAAC-3' |
| PLGF | 5'-GGTTACGCCCATCTTGCTCT-3' | 5'-GTATCTCTTACGTTACC-3' |
| CINC-1 | 5'-GAAGATAGATTGCACCGATG-3' | 5'-CATAGGCTCTACGATC-3' |
| LIX | 5'-GCATCTCATCTGTTACAGC-3' | 5'-GGGATAGAAGTCCCGCAGGAT-3' |
| Monokine | 5'-AGGGCTTCTCCGCTCTAT-3' | 5'-TAATCCCTGTCCTCCAC-3' |
| α-ADR | 5'-AAACTGTCCAATCTACCTC-3' | 5'-AGGCTTCTCCATGTTGGA-3' |
| β-actin | 5'-CGGAGTCAACGGATTTGGTC-3' | 5'-AGGCTTCTCCATGTTGGA-3' |

**Immunohistochemical staining.** Immunohistochemical staining was performed using the avidin-biotin-peroxidase technique. Paraffin-embedded tumor tissue sections (5 µm) were fixed with 10% paraformaldehyde for 2 h at 37°C and were subsequently deparaffinized in xylene and washed in PBS with Tween-20 (1%) three times at room temperature, followed by epitope retrieval using Tris-EDTA buffer solution (pH 9.0; Sigma-Aldrich; Merck KGaA; cat. no. SRE0063) for 60 min at 65°C. The paraffin sections were subjected to hydrogen peroxide (3%) for 10-15 min, and were subsequently blocked with 5% bovine serum albumin (Sigma-Aldrich; Merck KGaA; cat. no. ab16502), Ikk-β (1:1,000; cat. no. ab7870), IκBα (1:1,000; cat. no. ab16502; all Abcam) t 4°C for 12 h. All sections were washed three times and incubated with Alexa Fluor® 488-conjugated goat anti-rabbit IgG secondary antibody (1:1,000; cat. no. ab150077; Abcam) for 1 h at 37°C and were observed in six random fields of view under a fluorescence microscope at x40 magnification.

**Enzyme-linked immunosorbent assay (ELISA).** Plasma concentration levels of angiotensin, VCE and α-ADR from mice with gestational hypertension were detected by ELISA after receiving treatment with Candesartan, using commercialized ELISA kits for ACE (cat. no. DL-ACE2-Mu), α-ADR (cat. no. KL-EL0013915H; both Shanghai Kanglang Biotechnology Co., Ltd., Shanghai, China), according to the manufacturer's protocol. The absorbance was measured at a wavelength of 450 nm on an ELISA plate reader.

**Analysis of Th1/Th2.** Plasma concentration levels Th1/Th2 were measured using Th1/Th2 kit (LHC0015M, Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol.

**Activity of NF-κB.** Activity of NF-κB in vascular endothelial cells from healthy mice and mice with gestational hypertension was analyzed after receiving treatment with Candesartan. The activity of NF-κB was determined with the NF-κB kit (LHC0015M, Thermo Fisher Scientific, Inc.) according to the manufacturer's instructions.

**Statistical analysis.** All data are presented as mean ± standard error of three replicates within the same experiment and performed using GraphPad Prism software 5.0 (GraphPad Software, Inc., La Jolla, CA, USA). Statistical differences between experimental groups were analyzed by Student’s t-test or a one-way analysis of variance followed by Tukey's post-hoc test. P<0.05 was considered to indicate a statistically significant difference.

**Results**

**Effects of Candesartan treatment on expression of Ang-ITR in vascular endothelial cells.** To assess the impact of Candesartan on angiotensin release and Ang-ITR expression in a gestational hypertension model system, isolated endothelial cells were incubated with Candesartan. Angiotensin expression levels were upregulated in control vascular endothelial cells, whereas Candesartan significantly inhibited angiotensin release compared with control mice; there was no significant compared with healthy mice (Fig. 1A). In vitro assays indicated that homocysteine also induced angiotensin release compared with the control group, whereas Candesartan treatment inhibited angiotensin release compared with the control group (Fig. 1B). In addition, Ang-ITR expression levels (Fig. 1C) and angiotensin plasma concentration levels (Fig. 1D) were upregulated in control group compared with the healthy
group and were downregulated after Candesartan treatment in vivo compared with the control group. Furthermore, we analyzed expression levels of hypertension-related proteins. As demonstrated in Fig. 1E-H, VEGF, TGF-β, Ang-1 and PLGF expression levels were upregulated by Candesartan compared with the control group. Taken together, these results
suggested that Candesartan treatment may be beneficial for the downregulation of angiotensin release and Ang-IITR expression in vascular endothelial cells and mice with gestational hypertension induced by homocysteine.

**Candesartan treatment markedly improves sFlt-1, insulin resistance, and cardiovascular risk factors.** Gestational hypertension is characterized by widespread endothelial cell dysfunction, the progressive elevation of insulin resistance and higher expression of cardiovascular risk factors (27). Western blot analyses of sFlt-1 revealed that Candesartan treatment significantly decreased sFlt-1 expression levels compared with control vascular endothelial cells (Fig. 2A). Insulin resistance of mice was significantly improved in mice with gestational hypertension after treatment with Candesartan compared with the control group (Fig. 2B). In addition, renal prorenin receptor expression levels were also downregulated by Candesartan compared with the control group (Fig. 2C). Furthermore, cardiovascular risk factors including inflammation and oxidative stress were studied in the vascular endothelial cells after treatment with Candesartan. As demonstrated in Fig. 2D-F, tumor necrosis factor-α and interleukin-2 expression and the balance of Th1/Th2 was downregulated by Candesartan compared with the control group, in the serum of mice with gestational hypertension. Western blot analysis of oxidative stress demonstrated that expression levels of SOD (Fig. 1G) and ROS (Fig. 1H) were downregulated by Candesartan compared with control vascular endothelial cells. Taken together, these results suggested that Candesartan treatment markedly improved sFlt-1, insulin resistance and cardiovascular risk factors.

**Candesartan regulates soluble endoglin via the NF-κB signaling pathway.** To analyze the mechanism of Candesartan-mediated benefits for gestational hypertension, the NF-κB signaling pathway was investigated. Soluble endoglin expression was analyzed in vascular endothelial cells. As demonstrated in Fig. 3A, endoglin expression was downregulated by Candesartan compared with the control. Cytokine mRNA expressions levels of CINC-1 (Fig. 3B), LIX (Fig. 3C) and monokine (Fig. 3D) were decreased after treatment with Candesartan compared with the control. In addition, it was observed that p65, IKK-β and IκBα expression levels were upregulated by Candesartan in vascular endothelial cells, compared with the control (Fig. 3E). NF-κB activity was upregulated by Candesartan in vascular endothelial cells compared with the control (Fig. 3F). Inhibition of NF-κB activity by JSH23 reversed Candesartan-mediated reduction of sFlt-1 and endoglin expression levels (Fig. 3G, H). Taken together, the data suggested that Candesartan may mediate gestational hypertension via the endoglin-mediated NF-κB signaling pathway.

**Analysis of the efficacy of Candesartan treatment on mice with gestational hypertension induced by homocysteine.** To determine the therapeutic effects of Candesartan for gestational hypertension, a mouse model of gestational hypertension was established using homocysteine. As demonstrated in Fig. 4A, hypertension was decreased by Candesartan treatment compared with the control. Plasma concentrations of VCE and α-ADR were also downregulated by Candesartan treatment compared with the control, as determined by RT-qPCR (Fig. 4B and C). Candesartan treatment also upregulated NF-κB activation and nuclear translocation in vivo (Fig. 4D and E). Immunostaining assays revealed that p65, IKK-β and IκBα expression levels in vascular endothelial cells were increased after 14-day treatment with Candesartan (Fig. 4F). In addition, ELISA assays demonstrated that Candesartan treatment significantly inhibited aldosterone (Fig. 4G) and renin (Fig. 4H) release in serum in mice with gestational hypertension. Taken together, these results suggested that Candesartan treatment may be beneficial for the treatment of gestational hypertension induced by homocysteine.

**Discussion**

Reports have indicated angiotensin release and Ang-IITR expression serve a crucial role in the initiation and development of gestational hypertension, which respectively target angiotensin and α-ADR (28,29). Research also suggests that VCE and α-ADR are potential targets for the treatment of gestational hypertension (30). The underlying mechanism of formation of gestational arterial hypertension for women during pregnancy have been investigated and results have indicated that Ang-IITR contributes to the progression of gestational hypertension (31). Therefore, Ang-IITR may be a potential target and studies have revealed the efficacy of an Ang-IITR antagonist for hypertension in the clinic (32-34). In the present study, the therapeutic effects of Candesartan (an Ang-IITR antagonist) was investigated in pregnant mice with hypertension, which was induced by homocysteine. Although various previous studies have investigated the efficacy of Candesartan for the treatment of hypertension, the therapeutic effects of Candesartan for gestational hypertension is infrequently reported (35,36).

Candesartan is in a class of drugs called angiotensin II receptor antagonists. Candesartan prevents the constriction (narrowing) of veins and arteries and has been used in the treatment of essential hypertension (37). Currently, the classical RAS has been studied extensively for decades and has yielded numerous effective therapies for gestational hypertension and gestational hypertension-induced complications (19,38). Research has indicated that Ang-IITR blockers are antihypertensive drugs that may be an efficient way to improve the renin-angiotensin system by binding to Ang-IITR, leading to improvement of RAS, gestational hypertension and gestational hypertension-associated target organ damage in hypertensive animal models (39-41). Therefore, the present study determined whether Candesartan may have therapeutic effects on gestational hypertension. Candesartan treatment markedly improved gestational hypertension in a mouse model of gestational hypertension induced by homocysteine. The findings of the present study have suggested that Candesartan improves gestational hypertension via the NF-κB signaling pathway.

Previous studies revealed that the NF-κB signaling pathway may be involved in the biochemical metabolism of vascular endothelial cells and progression of gestational hypertension(42,43). Henke et al. (44) demonstrated that vascular endothelial cell-specific NF-κB inhibition not only attenuates hypertension, but may also improve hypertension-induced renal damage. Alonso et al. (45) revealed that an angiotensin II- and NF-κB-dependent mechanism may increase connexin 43 in murine arteries by targeting of renin-dependent
hypertension. In addition, the NF-κB signaling pathway may be involved in obesity-induced hypertension (46). The NF-κB pathway is also involved in C-reactive protein-induced effects on pulmonary arterial endothelial cells in chronic
thromboembolic pulmonary hypertension. Furthermore, the effect of antihypertensive drugs on the expression of NF-κB in monocrotaline-induced pulmonary arterial hypertension of rats have been investigated by Li et al (47). These reports
suggested that the NF-κB signaling pathway may be associated with the initiation and progression of hypertension.

The results of the present study suggested that the NF-κB signaling pathway influences Candesartan-mediated soluble endoglin and cytokine (CINC-1, LIX and monokine) expressions levels in vascular endothelial cells. Blocking of the NF-κB signaling pathway suppressed Candesartan-mediated improvement of sFlt-1 and endoglin expression levels. sFlt-1
and endoglin are two important predictive biomarkers of gestational hypertension (48,49). Alterations in sFlt-1 and endoglin expression levels may predict the progression of gestational hypertension (50,51). The results of the present study suggested that sFlt-1 and endoglin expression levels are altered after Candesartan treatment. Notably, gestational hypertension is markedly decreased after Candesartan treatment once daily for a total of 14 days.

To conclude, the present study investigated the clinical efficacy of Candesartan in mice with gestational hypertension induced by homocysteine. Although previous studies have reported the direct effects of Candesartan on hypertension, the present study investigated the effects of Candesartan in gestational hypertension and gestational hypertension-associated factors (52,53). This study suggested that Candesartan has a novel role in gestational hypertension management and an increasing number of preclinical reports show promising results (54-56). Of note, our results suggested that the NF-κB signaling pathway is involved in Candesartan-mediated initiation and progression of gestational hypertension. Overall, our findings suggested that mice with gestational hypertension treated by Candesartan exhibited beneficial effects for inflammation, oxidative stress and hypertension. However, future work should be performed in a larger cohort to support the data of the present study.

Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

The analyzed data sets generated during the study are available from the corresponding author on reasonable request.

Author's contributions

XZ performed the experiments. XW designed the experiments and analyzed the data.

Ethics approval and consent to participate

The present study was carried out in strict accordance with the recommendations in the Guide for Shandong Provincial Hospital affiliated to Shandong University. All surgery and euthanasia were performed to minimize suffering. This study was approved by the ethics committee of Shandong University and Taian City Central Hospital (Jinan, China).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Kennedy DA, Woodland C and Koren G: LeaD exposure, gestational hypertension and pre-eclampsia: A systematic review of cause and effect. J Obstet Gynaecol 32: 512-517, 2012.
2. Huang YH, Chen YF, Liang CC, Chang YL and Hsieh CC: Impetigo herpetiformis with gestational hypertension: A case report and literature review. Dermatology 222: 221-224, 2011.
3. Mohamad Razi ZR and Schindler AE: Review on role of progestogen (dydrogesterone) in the prevention of gestational hypertension. Horm Mol Biol Clin Investig 27: 73-76, 2016.
4. Pengo MF, Rossi GP and Steier J: Obstructive sleep apnea, gestational hypertension and preeclampsia: A review of the literature. Curr Opin Pulm Med 20: 588-594, 2014.
5. Zhu YC, Sun Y and Yang HX: Chronic hypertension superimposed on preeclampsia at 13 gestational weeks: A case report with review. Chin Med J (Engl) 125: 2067-2069, 2012.
6. Grandone E, Margaglione M, Colaizzo D, Cappucci G, Sciannameò N, Montanaro S, Paladini D, Martinelli P and Di Minno G: Prothrombotic genetic risk factors and the occurrence of gestational hypertension with or without proteinuria. Thromb Haemost 91: 487-491, 2004.
7. Vasapollo B, Novelli GP, Gagliardi G, Tiralongo GM, Pisani I, Manfioletto D, Giannini L and Valensise H: Medical treatment of early-onset mild gestational hypertension reduces total peripheral vascular resistance and influences maternal and fetal complications. Ultrasound Obstet Gynecol 40: 325-331, 2012.
8. Banhidy F, Acs N, Puho EH and Čzeizel AE: The efficacy of antihypertensive treatment in pregnant women with chronic and gestational hypertension: A population-based study. Hypertens Res 33: 460-466, 2010.
9. Schoenaker DA, Soedamah-Muthu SS and Mishra GD: The association between dietary factors and gestational hypertension and pre-eclampsia: A systematic review and meta-analysis of observational studies. BMC Med 12: 157, 2014.
10. Zainul Rashid MR, Lim JF, Nawawi NH, Luqman M, Zolkapli MF, Rangkuty HS, Mohamad Nor NA, Tamil A, Shah SA, Tham SW and Schindler AE: A pilot study to determine whether progesterone supplementation using dydrogesterone during the first trimester will reduce the incidence of gestational hypertension in primigravidae. Gynecol Endocrinol 30: 217-220, 2014.
11. Wang YA, Chuhtai AA, Farquhar CM, Pollock W, Lui K and Sullivan EA: Increased incidence of gestational hypertension and preeclampsia after assisted reproductive technology treatment. Fertil Steril 105: 920-926 e922, 2016.
12. Hua X, Zhang J, Guo Y, Shen M, Gadalet L, Janoudi G, Walker M and Wen SW: Effect of folic acid supplementation on gestational hypertension/preeclampsia: A systemic review and meta-analysis. Hypertens Pregnancy 35: 447-460, 2016.
13. Basaran A, Basaran M, Toputan B and Martin JN Jr: Effect of chorionic villus sampling on the occurrence of preeclampsia and gestational hypertension: An updated systematic review and meta-analysis. J Turk Ger Gynecol Assoc 17: 65-72, 2016.
14. Chinnathambi V, More AS, Hankins GD, Yallampalli C and Sathishkumar K: Gestational exposure to elevated testosterone and gestational hypertension: A review of the literature. J Reprod Med 59: 447-458, 2014.
15. Seremak-Mrozikiewicz A, Drews K, Chmara E, Mrozikiewicz PW and Slomko Z: Gestational hypertension (GH) and a1166c polymorphism of angiotensin II type 1 receptor signaling in rats. Biol Reprod 91: 6, 2014.
16. Chen PM, Lai TS, Chen PY, Lai CF, Wu V, Chiang WC, Chen YM, Wu KD and Tsai TJ: Renoprotective effect of combining pentoxifylline with angiotensin converting enzyme inhibitor or angiotensin II receptor blocker in advanced chronic kidney disease. J Formos Med Assoc 113: 219-226, 2014.
17. Mavrankenas TA, Gariani K and Martin PY: Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: An emerging paradigm in diabetic nephropathy: A systematic review. Eur J Intern Med 25: 173-176, 2014.
18. Tsutamoto T, Nishiyama K, Yamaji M, Kawahara C, Fujii M, Yamamoto T and Horie M: Comparison of the long-term effects of candesartan and olmesartan on plasma angiotensin II and left ventricular mass index in patients with hypertension. Hypertens Res 33: 118-122, 2010.
19. Kjeldsen SE, Stålhammar J, Hasvold P, Bodegard J, Ollson U and Russell D: Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension. J Hum Hypertens 24: 267-273, 2010.

20. Fogari R, Zoppi A, Salvadori SA, Mugellini A, Lazzari P, Santoro T and Derosa G: Fibrinolysis and insulin sensitivity in imipadril and candesartan (FISIC study) recipients with hypertension. Hypertens Res 34: 509-515, 2011.

21. Nishida Y, Takahashi Y, Nakayama T, Soma M, Kitamura N and Asai S: Effect of candesartan monotherapy on lipid metabolism in patients with hypertension: A retrospective longitudinal survey using data from electronic medical records. Cardiovasc Diabetol 9: 38, 2010.

22. Wai-Hoe L, Wing-Seng L, Ismail Z and Lay-Harn G: SDS-PAGE-based assay for screening of kidney stone disease. Biol Proced Online 11: 145-160, 2009.

23. Armstrong DW, Tse MY, O’Tierney-Ginn PF, Wong PG, Ventura NM, Janzen-Pang JJ, Matangi MF, Johri AM, Croy BA, Adams MA and Pang SC: Gestational hypertension in atrial natriuretic peptide knockout mice and the developmental origins of salt-sensitivity and cardiac hypertrophy. Regul Pept 186: 108-115, 2013.

24. Partyka R, Chmiel B, Sikora J, Grabowska T, Wróbel B, Praissner A, Pório A, Jawiecki P and Kokocinska D: Lipopsin, homocysteine and tissue polypeptide specific antigen in gestational hypertension. Mediators Inflamm 2007: 6073-6080, 2007.

25. Xiao S, Wang J and Xiao N: MicroRNAs as noninvasive biomarkers in bladder cancer detection: A diagnostic meta-analysis based on qRT-PCR data. Int J Biol Markers 31: e276-e285, 2016.

26. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.

27. Yang L, Zhang W, Zhang L, Zhang Y, Yang W, Qiao J, Chen G and Wang Y: Gestational hypertension risk evaluation based on epidemiological, biochemical, and hemodynamic parameters. Clin Exp Obstet Gynecol 40: 61-65, 2013.

28. Van Guilder GP, Pretorius M, Luther JM, Byrd JB, Hill K, Van W, Bailey AP and Manning RD Jr: Renal NF-kappaB activation and TNF-alpha upregulation correlate with salt-sensitive hypertension in Dahl salt-sensitive rats. Am J Physiol Integ Comp Physiol 291: R1817-R1824, 2006.

29. Ortiz LA, Champion HC, Lasky JA, Gambelli F, Gozal E, Hoyle GW, Beasley MB, Hyman AL, Friedman M and Kadowitz PJ: Enalapril protects mice from pulmonary hypertension by inhibiting TNF-mediated activation of NF-kappaB and AP-1. Am J Physiol Lung Cell Mol Physiol 282: L2109-L2121, 2002.

30. Henke N, Schmidt-Ullrich R, Dechend R, Park JK, Qadri F, Wieland M, Obst M, Gross V, Dietz R, Luft FC, et al: Vascular endothelial cell-specific NF-kappaB suppression attenuates hypertension-induced renal damage. Circ Res 101: 268-276, 2007.

31. Alonso F, K orttinger N, Mazzolari L, Simon A, Waeger B, Meda P and Huelger JA: An angiotensin II- and NF-kappaB-dependent mechanism increases connexin 43 in murine arteries targeted by renin-dependent hypertension. Cardiovasc Res 87: 166-176, 2010.

32. Purkasyatha S, Zhang G and Cui: Uncoupling the mechanisms of obesity and hypertension by targeting hypothalamic IKK-beta and NF-kB. Nat Med 17: 883-887, 2011.

33. Li XW, Guo B, Shen YY and Yang JR: Effect of chrysion on expression of NOX4 and NF-kappaB in right ventricle of monocrotaline-induced pulmonary arterial hypertension of rats. Yao Xue Xue Bao 50: 1128-1134, 2015 (In Chinese).

34. Carney EF: Hypertension: sFlt-1 removal seems to be beneficial in women with pre-eclampsia. Nat Rev Nephrol 11: 690, 2015.

35. Vaibhava-Diez AC, Blanco FJ, Ojio B, Langa C, Gonzalez-Nuñez M, Llano E, Pendas AM, Díaz M, Castrillo A, Lopez-Novoa JM and Bernabeu C: Oxytostrol-induced soluble endoglin release and its involvement in hypertension. Circulation 126: 2612-2624, 2012.

36. Daly AL, Robertson A, Johnson P, Middleton S, Bobek G, Sullivan C and Hennessy A: PP162. sFlt-1 controlled by CPAP: Health-care costs of losartan and candesartan in the primary treatment of hypertension. J Hum Hypertens 25: 228-233, 2011.